Regimen highly effective in difficult-to-treat populations, including cirrhotics and those with genotype 3 HCV infection.
For patients with GT3 HCV infection, high SVR12 rates with once-daily treatment regardless of cirrhosis, treatment experience, or treatment duration.
Glecaprevir/pibrentasvir for 12 or 16 weeks proved effective in cirrhotic patients with genotype 3 HCV infection, including those with treatment experience.
Baseline NS3 and NS5A RAVs did not affect achievement of SVR8 with MK-3682/grazoprevir/ruzasvir with or without RBV.
High SVR12 rates with once-daily, ribavirin-free treatment in cirrhotics and those with baseline resistance associated substitutions.
Glecaprevir/pibrentasvir similarly effective in HCV/HIV-coinfected patients and patients previously treated with sofosbuvir.
Triple-drug regimen effective regardless of treatment experience.
In this phase IIb trial, greater benefits observed in patients with greater disease activity treated with the CCR2/5 blocker.
Glecaprevir/pibrentasvir was effective in both treatment-naive and treatment experienced patients with or without compensated cirrhosis.
In a mixed population of cirrhotics and noncirrhotics, higher relapse rate in patients with genotype 1a HCV infection appeared to drive failure of 8-week SOF/VEL/voxilaprevir to meet criteria for noninferiority to 12-week SOF/VEL.
Treatment safe and tolerable with no discontinuations for study drug-related adverse events.
Significant clinical complications including death, decompensation, and liver transplantation observed with HBV reactivation in setting of HCV DAA therapy.
Selonsertib improved liver stiffness in patients with NASH and F2/F3 fibrosis, but had no effect on NAFLD Activity Score.